A61P 3/00
Drugs for disorders of the metabolism
Official title: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
A61P3/00 (Drugs for disorders of the metabolism) appears on 45,553 US grants and 69,319 published applications in this corpus.
Search patents in A61P- Granted patents
- 45,553
- Published applications
- 69,319
- Assignees
- 13,938
- Inventors
- 90,500
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 18 | 0 |
| 1977 | 33 | 0 |
| 1978 | 48 | 0 |
| 1979 | 45 | 0 |
| 1980 | 67 | 0 |
| 1981 | 85 | 0 |
| 1982 | 73 | 0 |
| 1983 | 51 | 0 |
| 1984 | 82 | 0 |
| 1985 | 85 | 0 |
| 1986 | 112 | 0 |
| 1987 | 126 | 0 |
| 1988 | 127 | 0 |
| 1989 | 182 | 0 |
| 1990 | 205 | 0 |
| 1991 | 208 | 0 |
| 1992 | 203 | 0 |
| 1993 | 153 | 0 |
| 1994 | 220 | 0 |
| 1995 | 269 | 0 |
| 1996 | 285 | 0 |
| 1997 | 415 | 0 |
| 1998 | 557 | 0 |
| 1999 | 550 | 0 |
| 2000 | 615 | 0 |
| 2001 | 734 | 285 |
| 2002 | 900 | 1343 |
| 2003 | 965 | 2155 |
| 2004 | 790 | 2811 |
| 2005 | 823 | 2876 |
| 2006 | 1112 | 2895 |
| 2007 | 1236 | 3133 |
| 2008 | 1301 | 3638 |
| 2009 | 1508 | 4102 |
| 2010 | 2143 | 4753 |
| 2011 | 2218 | 4411 |
| 2012 | 2607 | 4023 |
| 2013 | 2891 | 3357 |
| 2014 | 2919 | 3437 |
| 2015 | 2620 | 3084 |
| 2016 | 2182 | 2974 |
| 2017 | 2223 | 2705 |
| 2018 | 1939 | 2502 |
| 2019 | 1824 | 2549 |
| 2020 | 1681 | 2245 |
| 2021 | 1503 | 2041 |
| 2022 | 1148 | 1918 |
| 2023 | 974 | 1778 |
| 2024 | 940 | 1713 |
| 2025 | 984 | 1536 |
| 2026 | 574 | 1055 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Use of ionic polymers in biomass processing for preparation of animal feed additive6 Oct 2026US 12,751,470 B2Embion Technologies SA
- Methods for the treatment of cholesterol crystal embolization with cyclodextrins6 Oct 2026US 12,751,966 B2Beren Therapeutics P.B.C.
- Methods and compositions of chondrisomes6 Oct 2026US 12,751,977 B2Children's Medical Center Corporation
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Benzimidazole compound for the treatment of metabolic disorders29 Sep 2026US 12,746,227 B2Ache Laboratorios Farmaceuticos S/A
- Lipolytic and antiadipogenic coumarin derivatives8 Oct 2026US 2026/0306446 A1Karl-Franzens-Universität Graz
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Alk7 combination treatments8 Oct 2026US 2026/0306628 A1
- Synthetic mmab genes and aav vectors to treat cobalamin b deficiency8 Oct 2026US 2026/0308538 A1The United States of America, as represented by the Secretary, Department of Health and Human Servi
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Diabetes management system1,937US 6,544,212 B2Roche Diagnostics GmbH · 2003
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004